Tenofovir was. approved by the Food and Drug Administration (FDA) for the treatment of chronic B hepatitis in 2008. To evaluate the primary efficacy of Tenofovir, 190 patients treated by Topflovir (26 cases), Planovir (12 cases), Tenofovir Stada (129 cases) and Getino-B (23 cases) were enrolled in this study. HBV DNA, AST, ALT, total Bilirubin were measured at 0, 1, 3, 6, 12, 24 months during the course of therapy. Results showed that 155/190 (81.6 percent) patients were treated by one of following antiviral drugs: Lamivudine, Adefovir or Entecvir. Level of HBV DNA before treatment was 4.5 x 10 exponent 8 + or - 2.3 x 10 exponent 3 copies/ml. After 1 month of Tenofovir therapy, 190/190 (100 percent) patients had HBV DNA decreased at least 210g, with 180/190 (94.7 percent) patients decreased more than 310g
After 3 months of therapy, 171/190 (90 percent) patients had HBV DNA 100 copies/ml
After 6 months of therapy, 190/190 (100 percent) had HBV DNA 100 copies/ml. The average of follow-up of 12 months (6-26 months) saw no antiviral resistance
no side effect was observed. There is no significant difference between Topflovir, Planovir, Tenofovir Stada and Getino-B in the treatment of chronic B hepatitis. Thus, Tenofovir is an efficacy medication for the treatment of chronic B hepatitis.